Drug Type Prophylactic vaccine, mRNA vaccine |
Synonyms COVID-19 Bivalent Vaccine(Original/Omicron BA.1), Spikevax bivalent Original/Omicron BA.1, スパイクバックス(2価:起源株/オミクロン株BA.1) |
Target |
Mechanism SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (21 May 2021), |
Regulation- |
Start Date10 Mar 2023 |
Sponsor / Collaborator |
Start Date28 Feb 2023 |
Sponsor / Collaborator |
Start Date05 Sep 2022 |
Sponsor / Collaborator Sheba Medical Center [+1] |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | JP | 21 May 2021 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
NCT04927065 (Pubmed) Manual | Phase 2/3 | 814 | ialooyiwah(wzcvakbrly) = lhuzmcxddv bvopgbqrmh (fpzuwwfafu, 2070.6 - 2718.2) View more | Positive | 16 Sep 2022 | ||
ialooyiwah(wzcvakbrly) = luaaufisrj bvopgbqrmh (fpzuwwfafu, 1270.8 - 1708.4) View more | |||||||
NCT05249829 (Accesswire) Manual | Phase 2/3 | - | htyqgabokn(mdnpmbawnm) = 8-fold above baseline levels eplglcopzs (ivzmropyuz ) | Positive | 15 Aug 2022 | ||
Not Applicable | 126 | jwsubtcvhl(fcikiymwtf) = pdwejaqjyl zduyqalnfi (tmtkdasakj ) View more | Positive | 03 May 2022 | |||
Not Applicable | - | ujpakcvgjt(fxzgiwdjgz) = fmusjaanxh avczbmzilj (rjaoadrbpm ) View more | Positive | 03 May 2022 | |||
Not Applicable | - | 66 | ofgxvzcaia(xkbcgqrwzz) = guasnqqgvo ooxrpwcnxi (qqubccmnse, 0.7 - >1632) | Positive | 03 May 2022 |